First National Trust’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $620K | Sell |
6,859
-11,492
| -63% | -$963K | 0.02% | 261 |
|
|
2026
Q1 | $1.47M | Buy |
18,351
+7,859
| +75% | +$648K | 0.05% | 220 |
|
|
2025
Q4 | $894K | Buy |
+10,492
| New | +$861K | 0.03% | 255 |
|
|
2025
Q3 | – | Sell |
-3,224
| Closed | -$252K | – | 410 |
|
|
2025
Q2 | $252K | Sell |
3,224
-480
| -13% | -$35.8K | 0.01% | 348 |
|
|
2025
Q1 | $268K | Buy |
3,704
+172
| +5% | +$12.3K | 0.01% | 339 |
|
|
2024
Q4 | $261K | Sell |
3,532
-218
| -6% | -$15.3K | 0.01% | 349 |
|
|
2024
Q3 | $247K | Sell |
3,750
-428
| -10% | -$31.1K | 0.01% | 358 |
|
|
2024
Q2 | $386K | Buy |
4,178
+72
| +2% | +$6.38K | 0.02% | 306 |
|
|
2024
Q1 | $392K | Buy |
4,106
+611
| +17% | +$51.3K | 0.02% | 297 |
|
|
2023
Q4 | $266K | Buy |
3,495
+53
| +2% | +$3.69K | 0.01% | 333 |
|
|
2023
Q3 | $238K | Sell |
3,442
-115
| -3% | -$9.24K | 0.01% | 340 |
|
|
2023
Q2 | $336K | Sell |
3,557
-297
| -8% | -$25.8K | 0.02% | 305 |
|
|
2023
Q1 | $319K | Buy |
3,854
+141
| +4% | +$11.1K | 0.02% | 307 |
|
|
2022
Q4 | $277K | Buy |
3,713
+236
| +7% | +$18.2K | 0.01% | 315 |
|
|
2022
Q3 | $287K | Sell |
3,477
-94
| -3% | -$9.04K | 0.02% | 307 |
|
|
2022
Q2 | $340K | Sell |
3,571
-373
| -9% | -$38.6K | 0.02% | 289 |
|
|
2022
Q1 | $464K | Sell |
3,944
-135
| -3% | -$15.1K | 0.02% | 273 |
|
|
2021
Q4 | $528K | Buy |
4,079
+22
| +0.5% | +$2.57K | 0.03% | 267 |
|
|
2021
Q3 | $459K | Sell |
4,057
-403
| -9% | -$46K | 0.03% | 266 |
|
|
2021
Q2 | $462K | Sell |
4,460
-692
| -13% | -$65.2K | 0.03% | 270 |
|
|
2021
Q1 | $431K | Buy |
5,152
+71
| +1% | +$6K | 0.03% | 267 |
|
|
2020
Q4 | $464K | Sell |
5,081
-351
| -6% | -$29.1K | 0.03% | 241 |
|
|
2020
Q3 | $434K | Sell |
5,432
-303
| -5% | -$23.6K | 0.03% | 225 |
|
|
2020
Q2 | $396K | Sell |
5,735
-925
| -14% | -$65.7K | 0.03% | 228 |
|
|
2020
Q1 | $419K | Sell |
6,660
-3,489
| -34% | -$252K | 0.04% | 213 |
|
|
2019
Q4 | $789K | Sell |
10,149
-2,001
| -16% | -$156K | 0.06% | 187 |
|
|
2019
Q3 | $891K | Sell |
12,150
-3,081
| -20% | -$216K | 0.08% | 178 |
|
|
2019
Q2 | $938K | Sell |
15,231
-37,638
| -71% | -$2.28M | 0.09% | 179 |
|
|
2019
Q1 | $3.37M | Sell |
52,869
-46,200
| -47% | -$2.64M | 0.34% | 86 |
|
|
2018
Q4 | $5.06M | Buy |
99,069
+30,231
| +44% | +$1.53M | 0.56% | 55 |
|
|
2018
Q3 | $4M | Buy |
68,838
+6,849
| +11% | +$335K | 0.41% | 75 |
|
|
2018
Q2 | $3.01M | Buy |
61,989
+3,525
| +6% | +$165K | 0.33% | 92 |
|
|
2018
Q1 | $2.72M | Buy |
58,464
+9,570
| +20% | +$416K | 0.31% | 96 |
|
|
2017
Q4 | $1.84M | Buy |
48,894
+21,402
| +78% | +$785K | 0.2% | 123 |
|
|
2017
Q3 | $1M | Buy |
27,492
+3,249
| +13% | +$124K | 0.12% | 174 |
|
|
2017
Q2 | $955K | Buy |
24,243
+2,064
| +9% | +$75.3K | 0.12% | 180 |
|
|
2017
Q1 | $695K | Buy |
22,179
+6,966
| +46% | +$218K | 0.09% | 194 |
|
|
2016
Q4 | $475K | Buy |
15,213
+3,528
| +30% | +$114K | 0.07% | 221 |
|
|
2016
Q3 | $469K | Buy |
+11,685
| New | +$440K | 0.07% | 203 |
|
Other funds holding EW
First National Trust's EW Position: Q2 2026 in Review
First National Trust reduced its Edwards Lifesciences (EW) stake by 63% in Q2 2026, selling an estimated $963K and leaving 6,859 shares worth $620K. The position accounts for 0.02% of the portfolio, ranked #261.
First National Trust first reported a position in EW in Q3 2016 and has held it in 39 quarters since. The position peaked at $5.06M in Q4 2018. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- First National Trust held 6,859 shares of Edwards Lifesciences worth $620K as of Q2 2026.
- First National Trust sold 11,492 Edwards Lifesciences shares in Q2 2026, an estimated $963K.
- Edwards Lifesciences made up 0.02% of First National Trust's portfolio in Q2 2026, its #261 holding.
- First National Trust first reported a position in Edwards Lifesciences in Q3 2016 and has held it in 39 quarters since.
- First National Trust's Edwards Lifesciences position peaked at $5.06M in Q4 2018.
- 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on First National Trust's 13F filing for Q2 2026, filed 30 Jul 2026.